UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect

Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS assumed coverage of Arcellx with a Buy rating and $100 price target as the firm assumed coverage on 22 small-to-mid cap biotech names. Contending that biotech fundamentals are now inflecting after a rough period, UBS expects investor confidence to recover and sees this positioning the sector for strong performance in 2026.

Earlier on December 22, Wells Fargo initiated coverage of Arcellx Inc. (NASDAQ:ACLX) with an Overweight rating and a $100 price target, identifying the company’s anito-cel as a future pillar in the treatment of multiple myeloma.

Wells Fargo contends that anito-cel is positioned to capture a majority of the BCMA CAR-T market for fourth-line multiple myeloma due to its attractive efficacy and safety profile, with rapid uptake expected upon its projected launch in 2026. Furthermore, the firm remains optimistic about Arcellx’s broader opportunities within the CAR-T space, notwithstanding recent data from industry competitors.

Arcellx Inc. (NASDAQ:ACLX), together with its subsidiary, develops various immunotherapies for patients with cancer and other incurable diseases in the US.

While we acknowledge the potential of ACLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.